Medicxi Announces €500 Million Fund V
New fund will continue Medicxi’s successful asset-centric company creation and investment strategy.
LONDON, UK — November 14, 2025 — Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi’s pioneering asset-centric investment model.
